Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Priothera SAS (France)
Homepage:
priothera.com
Alternate names:
Priothera,
Priothera SAS
ROR:
016y5ff97
OpenAlex ID:
I4405267092
Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy
2022
·
Simone Dertschnig
, Peter Gergely
, et al.
·
Transplantation and Cellular Therapy
·
22
PDF
Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne
2022
·
Diane M. Thiboutot
, Noah Craft
, et al.
·
Journal of Dermatological Treatment
·
15
Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation
2023
·
Simone Dertschnig
, Jakob Passweg
, et al.
·
Cellular Immunology
·
8
MO-TRANS: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of Mocravimod (MOC) As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
2024
·
Gabriela Sanchez-Petitto
, Maria Calbacho
, et al.
·
Blood
·
4
PDF
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Oral Dose Study of Mocravimod: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Participants
2026
·
Dymphy Huntjens
, Dirk Klingbiel
, et al.
·
medRxiv
·
3
PDF
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of mocravimod in Healthy Volunteers
2026
·
Dymphy Huntjens
, Dirk Klingbiel
, et al.
·
medRxiv
·
2
PDF
Clinical Assessment of Mocravimod As a Victim of Drug-Drug Interactions Via CYP3A Metabolism and Transporters
2024
·
Dymphy Huntjens
, Stephan Oehen
, et al.
·
Blood
·
2
MO-TRANS update: A randomized, double-blind, placebo-controlled, multi-center phase III study of mocravimod (MOC) as maintenance treatment in AML patients undergoing allogeneic hematopoietic cell transplantation
2025
·
Marcos de Lima
, Gabriela Sanchez-Petitto
, et al.
·
Blood
·
1
Clinical assessment of mocravimod as a victim of drug–drug interactions via CYP3A4 metabolism and transporters
2025
·
Dymphy R. Huntjens
, Stephan Oehen
, et al.
·
Clinical Pharmacology in Drug Development
·
1
PDF
MO-TRANS: A Phase 2b Placebo-Controlled Study of Mocravimod As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant
2022
·
Marcos de Lima
, Florent Malard
, et al.
·
Blood
·
1
Pharmacokinetics, Pharmacodynamics and Safety of Mocravimod After Single and Multiple Oral Dosing in Healthy Japanese Participants
2026
·
Dymphy Huntjens
, Dirk Klingbiel
, et al.
·
Research Square
PDF
Titration regimens mitigate mocravimod-induced negative chronotropic effect while preserving the pharmacokinetic and pharmacodynamic properties
2026
·
Dymphy Huntjens
, Dirk Klingbiel
, et al.
·
medRxiv
PDF
P1282: Mocravimod Improves Overall Survival in Aml Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
2023
·
Michael Medinger
, Jakob Passweg
, et al.
·
HemaSphere
S235: a Two-part, Single- and Two-arm Randomized, Open-label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the S1p Receptor Modulator Krp203 in Subjects With Hematological Malignancies
2022
·
S. dertschnig
, J. finke
, et al.
·
HemaSphere
Show more works
View as search
Works count:
14
Citation count:
59
Year
Topic
Type